Digallic acid for reduction of inflammatory cytokine activity

Abstract

The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.

1 . A method for reducing inflammatory cytokine activity in a human patient, comprising:
 administering to a human patient in need of reduction of inflammatory cytokine activity a pharmaceutical composition comprising an effective amount of digallic acid.   
     
     
         2 . The method of  claim 1 , wherein one or both of IL-6 and TNF-α are reduced as a result of said administration. 
     
     
         3 . The method of  claim 2 , wherein IL-6 is reduced as a result of said administration. 
     
     
         4 . The method of  claim 2 , wherein TNF-α is reduced as a result of said administration.